Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?
نویسندگان
چکیده
منابع مشابه
Clearance of plasma proprotein convertase subtilisin/kexin 9 by low-density lipoprotein apheresis.
Clearance of Plasma Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein Apheresis To the Editor: Proprotein convertase subtilisin/kexin 9 (PCSK9) is a secreted protein that modulates plasma low-density lipoprotein (LDL) concentrations in part by facilitating degradation of the LDL receptor. It also mediates degradation of the very-low density lipoprotein receptor and apolipoprot...
متن کاملLoss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
RATIONALE Lipoprotein apheresis (LA) reduces low-density lipoprotein (LDL) levels in patients with severe familial hypercholesterolemia (FH). We have recently reported that >30% of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) is bound to LDL, thus we predicted that LA would also reduce plasma PCSK9 levels by removing LDL. OBJECTIVE Pre- and post-apheresis plasma from 6 patients wit...
متن کاملHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
Atherosclerotic cardiovascular disease is the main cause of mortality and morbidity in the world. Plasma levels of low density lipoprotein cholesterol (LDL-C) are positively correlated with the risk of atherosclerosis. High plasma LDL concentrations in patients with hypercholesterolemia lead to build-up of LDL in the inner walls of the arteries, which becomes oxidized and promotes the formation...
متن کاملPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Reduction in low-density lipoprotein cholesterol (LDL-C), mainly with statins, has decreased the risk of cardiovascular events over the last few decades. However, there are several patient populations that warrant further decrease in LDL-C by additional cholesterol-lowering therapy other than statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs that...
متن کاملLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
Elevated levels of lipoprotein(a) (Lp(a)) have been identified as an independent risk factor for coronary heart disease. Plasma Lp(a) levels are reduced by monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). However, the mechanism of Lp(a) catabolism in vivo and the role of PCSK9 in this process are unknown. We report that Lp(a) internalization by hepatic HepG...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Preventive Cardiology
سال: 2018
ISSN: 2047-4873,2047-4881
DOI: 10.1177/2047487318817671